TMEM127 and ovarian cancer: Notably, TMEM127 mutations or reduced expression are also seen at low frequencies in a number of other tumor types (e.g. endometrial, liver, breast, kidney, ovarian cancers; Tate et al., 2019) where TMEM127 contributions have not yet been specifically recognized, suggesting that aberrant accumulation and activation of growth factor receptors could also impact these tumors.